Scarica l'app Stockscreener
14.36
0.63%
0.09
Precedente Chiudi:
$14.27
Aprire:
$14.5
Volume 24 ore:
4.39M
Relative Volume:
2.30
Capitalizzazione di mercato:
$48.22B
Reddito:
$30.25B
Utile/perdita netta:
$1.37B
Rapporto P/E:
33.73
EPS:
0.4257
Flusso di cassa netto:
$5.08B
1 W Prestazione:
-6.27%
1M Prestazione:
+0.14%
6M Prestazione:
+4.21%
1 anno Prestazione:
+7.40%
Intervallo 1D:
$14.34
$14.57
Intervallo di 1 settimana:
$14.21
$15.43
Portata 52W:
$12.57
$15.43
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Confronta TAK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-07-19 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-10-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Iniziato | Cowen | Market Perform |
| 2019-08-15 | Downgrade | Daiwa Securities | Outperform → Neutral |
Mostra tutto
Takeda Pharmaceutical Co Adr Borsa (TAK) Ultime notizie
Financial Metrics Unveiled: Topgolf Callaway Brands Corp (MODG)’s Key Ratios in the Spotlight - DWinneX
Ratios Reveal: Breaking Down Takeda Pharmaceutical Co ADR (TAK)’s Financial Health - DWinneX
Balance Sheet Insights: Nuveen Churchill Direct Lending Corp (NCDL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs - Benzinga
TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - knoxdaily.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Takeda Pharmaceutical Co ADR [TAK] Insider Activity: An Update for Investors - knoxdaily.com
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? - Yahoo Finance
A significant driver of top-line growth: Takeda Pharmaceutical Co ADR (TAK) - Sete News
Nothing is Better Than C.H. Robinson Worldwide, Inc (CHRW) stock at the moment - Sete News
Takeda Pharmaceutical Co ADR Inc. (TAK) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Carmax Inc: Analyzing KMX Stock Trends - investchronicle.com
Klaviyo Inc (KVYO) Stock: The Story of a 52-Week Stock Range - investchronicle.com
You might want to take a look at Denison Mines Corp (DNN) now - Sete News
A Look at Cousins Properties Inc (CUZ) Shares in the Recent Past Indicates Growth - Sete News
A better buy-in window may exist right now for Cheesecake Factory Inc (CAKE) - Sete News
Stocks of CN Energy Group Inc (CNEY) are poised to climb above their peers - Sete News
Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - knoxdaily.com
Cintas Corporation [CTAS] Insider Activity: An Update for Investors - knoxdaily.com
TAK vs. DSNKY: Which Stock Is the Better Value Option? - Yahoo Finance
Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - MSN
Asian ADRs Take A Hit As S&P Asia 50 Dips - Finimize
Morgan Stanley lifts Takeda stock rating, raises target to JPY5,500 - Investing.com
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now? - Yahoo
PD Stock on the Rise: A Promising Investment - The InvestChronicle
Vital Energy Inc (VTLE) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
China Liberal Education Holdings Ltd: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities - Value the Markets
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
Charles Schwab Trying To Close In On Key Technical Measure - Inkl
Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Takeda Pharmaceutical ADR Trying To Close In On Key Technical Measure - Investor's Business Daily
XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine… - MSN
Ex-Intern Becomes Billionaire in Australia Pharmacy Merger - MSN
Vyvanse Leaks: Beyond The Headlines - truthorfiction.com
IgA nephropathy Clinical Trials and Pipeline 2025: EMA, PDMA, - openPR
IgA nephropathy Clinical Trials and Pipeline Assessment: EMA, - openPR
Takeda Pharmaceutical Co Adr Azioni (TAK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.61%
1.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):